PepGen to Participate in Upcoming Investor Conferences

PEPG 11.04.2024

Full Press ReleaseSEC FilingsOur PEPG Tweets

About Gravity Analytica

Recent News

  • 12.16.2024 - PepGen Announces Clinical Hold in the U.S. on IND Application to Initiate CONNECT2-EDO51 Phase 2 Study of PGN-EDO51 for Duchenne Muscular Dystrophy
  • 11.21.2024 - PepGen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Senior Vice President, Clinical Development
  • 11.19.2024 - Stifel 2024 Healthcare Conference

Recent Filings

  • 12.16.2024 - EX-99.1 EX-99.1
  • 12.16.2024 - 8-K Current report
  • 11.14.2024 - SC 13G Statement of Beneficial Ownership by Certain Investors
PDF Version

BOSTON--(BUSINESS WIRE)--Nov. 4, 2024--PepGen Inc.(Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that management will participate in the following upcoming investor conferences:

  • Guggenheim'sInaugural Healthcare Innovation Conference(Boston, MA)
    • Monday, November 11, 2024at1:00 p.m. ET, Fireside Chat
  • Stifel 2024 Healthcare Conference (New York, NY)
    • Tuesday, November 19, 2024at11:30 a.m. ET, Fireside Chat

A webcast of each conference presentation will be available on the “Events & Presentations” page within the Investors section of thePepGenwebsite athttps://investors.pepgen.com/. Replays of the webcasts will be available on thePepGenwebsite for 90 days following the presentation dates.

AboutPepGen

PepGenis a clinical-stage biotechnology company advancing the next-generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases. PepGen’s Enhanced Delivery Oligonucleotide (EDO) platform is founded on over a decade of research and development and leverages cell-penetrating peptides to improve the uptake and activity of conjugated oligonucleotide therapeutics. Using these EDO peptides, we are generating a pipeline of oligonucleotide therapeutic candidates designed to target the root cause of serious diseases.

For more information, please visitwww.pepgen.com. FollowPepGenonLinkedInandX.

View source version onbusinesswire.com:https://www.businesswire.com/news/home/20241104983620/en/

Investor ContactDave Borah, CFASVP, Investor Relations and Corporate Communicationsdborah@pepgen.com

Media ContactJulia DeutschLyra Strategic AdvisoryJdeutsch@lyraadvisory.com

Source:PepGen Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com